Translating Novel siRNA & microRNA Drugs from Bench To Bedside

As Novartis' landmark $12 billion acquisition of Avidity Biosciences and GSK's strategic $85 million partnership for an RNA-based COPD treatment signal unprecedented confidence in the modality, the focus now sharpens on overcoming its final frontier: delivery beyond the liver. This challenge is the central bottleneck to unlocking a broader therapeutic revolution, fueling a new wave of innovation from startups like Aerska, which secured $21 million to pioneer RNA interference (RNAi) for brain diseases.

Returning as the industry's premier dedicated forum, the RNAi-Based Therapeutics Summit is the only event uniting the entire RNA interference ecosystem to translate the next wave of siRNA and microRNA drugs from bench to bedside. This year's conversation went beyond the liver, focusing on the novel strategies turning extra-hepatic delivery into a clinical reality, from next-generation LNPs and conjugates to emerging platforms targeting the lungs, CNS, and skeletal muscle.

Attendees joined 80+ senior decision-makers from AbbVie, Alnylam, Judo Bio, Ceria Therapeutics and more to gain the data-focused insights and high-value connections needed to overcome stability challenges, de-risk clinical translation, and position your pipeline at the forefront of the next therapeutic revolution.